Title:
アルキルカルバモイルナフタレンイルオキシオクテノイルヒドロキシアミドまたはその誘導体の薬学的に許容可能な塩及びその製造方法
Document Type and Number:
Japanese Patent JP6895548
Kind Code:
B2
Abstract:
The present invention relates to method for producing a pharmaceutically acceptable salt of alkylcarbamoyl naphthalenyloxy octenoylhydroxyamide, having improved moisture stability while maintaining the characteristics, such as the efficacy and effective dose, of a pharmaceutically acceptable salt of alkylcarbamoyl naphthalenyloxy octenoylhydroxyamide. In addition, the present invention can simplify the production and manufacturing process of a formulation by improving hygroscopicity.
Inventors:
Cho, Jepyeon
Jung, Yongho
Cho, Jun Myung
Jung, Yongho
Cho, Jun Myung
Application Number:
JP2019569941A
Publication Date:
June 30, 2021
Filing Date:
April 18, 2018
Export Citation:
Assignee:
CRYSTALGENOMICS, INC.
International Classes:
C07C259/06; A61K31/165; A61P35/00
Domestic Patent References:
| JP2009513697A | ||||
| JP2010502610A | ||||
| JP4128223A | ||||
| JP2011504890A | ||||
| JP2010509208A | ||||
| JP2008528530A |
Foreign References:
| KR1020110096028A |
Other References:
小野誠,塩選択の現状分析,薬剤学,2013年,73(3),,176-182
Hwang, Jung Jin et al.,A novel histone deacetylase inhibitor, CG0006, induces cell death through both extrinsic and intrinsic apoptotic pathways,Anti-Cancer Drugs ,2009年,20(9),,815-821
Hwang, Jung Jin et al.,A novel histone deacetylase inhibitor, CG0006, induces cell death through both extrinsic and intrinsic apoptotic pathways,Anti-Cancer Drugs ,2009年,20(9),,815-821
Attorney, Agent or Firm:
Kiyoji Kuzuwa